


Cambio constitutes the operating entities under Sanolium AB. All figures in () refer to the comparable figures from previous year. The pro forma for the full year 2019 includes operating activities from January 1st to February 20th. The pro forma prior to 2019 refers to Cambio Group operating activities in periods prior to 2019.

Revenue in the third quarter amounted to 158.5 MSEK, representing growth of 15.3%

Q3, July - September 2020

- Revenue amounted to 158.5 (137.5) MSEK in the third quarter, representing growth of 15.3%
- Adjusted EBITDA amounted to 43.7 (32.6) MSEK, representing growth of 34.0%
- Cambio acquired 100% of the shares in MittVaccin, a Swedish company within the vaccination record business


Q3, revenue



January - September 2020

- Revenue during January - September amounted to 518.8 (20 Feb - 30 Sep, 2019; 334.7) MSEK
- Adjusted EBITDA amounted to 143.9 (20 Feb -30 Sep 2019; 67.1) MSEK

Pro forma revenue, MSEK



Key figures

MSEK	Q3 2020	Q3 2019	Jan-Sep 2020	Feb-Sep 2019
Revenue	158.5	137.5	518.8	334.7
Adjusted EBITDA	43.7	32.6	143.9	67.1
Adjusted EBITDA-margin	27.6%	23.7%	27.7%	20.0%
EBIT	2.2	-45.7	19.7	-93.4
Financial net	-6.7	-4.6	-20.0	-13.9
Income before tax	-4.5	-50.3	-0.3	-107.3
Net income	-3.8	-45.5	-1.0	-95.3

Sanolium AB is the parent company in the Cambio Group, since February 20, 2019. The largest operating subsidiary in that group is Cambio Healthcare Systems which was founded in 1993 to deliver comprehensive IT solutions for healthcare organizations. Today, Cambio is an e-health company providing smart, reliable and user-friendly solutions to improve healthcare and patient safety with a market leading position in the Nordics including more than 100 000 users. We are committed to improve healthcare and patient safety.

CEO's Comments

The increased demand for our solutions reflects the need for increased digitalization in health- and social-care. The regions and municipalities in Sweden need to invest more in IT than they have done historically. Cambio has the products and services to bridge the technical gap that the regions and municipalities face, and to enable tomorrow's health- and social-care. Together with our customers we contribute to a better and a healthier society.

About Cambio

Cambio is well positioned to become the Nordic leader within eHealth. Today we principally serve Nordic regions and municipalities by delivering their core healthcare IT system.

The constantly growing and aging population creates a need for increased productivity and efficiency in health- and social-care and in a world with limited resources this can be achieved by increased digitalization.

The growing gap between the available technologies and the technical solutions used by healthcare providers today can and will be bridged through Cambio's superior solutions.

About third quarter

As a result of the spread of the Corona virus many people are living with challenging conditions and many have lost their lives. Cambio's most important task under the current circumstances is to ensure our products fulfil their purpose without any interruptions and enable doctors and nurses to spend more time focusing on critical patients.

The impact of Covid-19 on society and businesses continues to be severe. Cambio's priorities under the current circumstances are to support our customers, to ensure our products fulfil their purpose without any interruptions and to protect the health and safety of our employees. Cambio has, together with our existing customers, taken actions to directly address Covid-19 effects with our software to make it possible to decrease administrative time, share information with municipalities and provide more intensive care beds.

Direct interactions with our customers remain on a low level making it harder to sell new projects and obtain delivery approvals. This has impacted project timings and therefore revenue recognition in the third

quarter. We have also seen some impact on our operational efficiency and productivity. With the spread of Covid-19 accelerating in the beginning of the fourth quarter we anticipate further and potentially larger impacts on the timing of projects during the remainder of the year.

In the third quarter, Cambio continued to deliver on its M&A strategy acquiring MittVaccin. Through the acquisition, Cambio gains the potential to fill an upcoming gap for a nationwide vaccination solution. MittVaccin also adds to Cambio's revenues and provides for a product with international appeal. This is the second acquisition in two consecutive years, through which Cambio's product portfolio is broadened and in line with the interests and requirements of Cambio's customer base.

We look forward to strengthening our position as a natural partner to our customers, to help them do their job more efficiently!



Peter Gille, CEO

Third quarter

Revenue in the third quarter amounted to 158.5 (137.5) MSEK, representing growth of 15.3%. Support and maintenance fees constitute the largest part of the revenue. License revenue and Professional services revenue are attributable to the development of the existing product as well as to the SUSSA project.

Adjusted EBITDA in the third quarter amounted to 43.7 (32.6) MSEK resulting in an adjusted EBITDA margin of 27.6 (23.7)%.

Employee related expenses amounted to 95.6 (88.8) MSEK, corresponding to an increase of 7.7%. The number of fulltime employees rose to 730 in the third quarter, an increase of 9% from the comparable figure last year. The number of employees by end of the third quarter amounted to 741, of which 373 were employed in Sweden and 320 were females.

Depreciation and amortization amounted to 38.2 MSEK, of which 27.3 MSEK refers to amortization of intangible assets with regard to M&A activities, 5.5 MSEK refers to financial leases and 2.0 MSEK refers to amortization of capitalized R&D. The remaining depreciation of tangible assets amounted to 3.4 MSEK.


Non-recurring items amounted to 3.3 MSEK, consisting of 2.2 MSEK linked to the introduction of a new ERP system and 1.1 MSEK for other non-recurring items.

Significant events and outlook

In the third quarter, Cambio continued to deliver on its M&A strategy acquiring MittVaccin (company reg. no. 556883-3411). The purchase consideration amounts to 36.1 MSEK of which 26.8 MSEK was paid in cash and the remaining 9.3 MSEK in newly issued shares. For the financial period July 2018 – Dec 2019 the company's turnover amounted to 4.8 MSEK. A detailed statement regarding the acquired values will follow in the 2020 annual report.

Through the acquisition, Cambio gains the potential to fill an upcoming gap for a nationwide vaccination solution which is expected to accelerate during 2021. MittVaccin also adds scalable revenues and a product with international appeal. MittVaccin is consolidated from the beginning of September and had a neutral contribution to Cambio's EBITDA in the third quarter. MittVaccin is expected to contribute positively to Cambio's EBITDA in 2021.

During the second quarter of 2020, Cambio agreed with the remaining option regions within the Sussa customer group, to deliver Cambio's EHR solution. Including those regions, Cambio covers almost all regions in Sweden, except the regions Skåne, Stockholm, Gotland and Västra Götaland. The first sign-on settlement is executed and the net effect from that payment and the purchase consideration for MittVaccin resulted in a positive cashflow of approximately 30 MSEK in the third quarter. There were no other significant events to report in Q3 2020.



Covid-19 implications on the business

Cambio provides business-critical software that many doctors and nurses in Sweden use on a daily basis to deal with healthcare matters, including the current Covid-19 pandemic. Cambio's most important task under the current circumstances is to ensure our products fulfil their purpose without any interruptions or down time.

Direct interactions with our customers remain on a low level making it harder to sell new projects and obtain delivery approvals. This has impacted project timings and therefore revenue recognition in the third quarter. We have also seen some impact on our operational efficiency and productivity. With the spread of Covid-19 accelerating in the beginning of the fourth quarter we anticipate further and potentially larger impacts on the timing of projects during the remainder of the year.



Long-term outlook

In response to the global trend of a constantly growing and aging population there is a real need to invest in health- and social-care. In a world with limited resources these areas of care face increasing pressure to become more productive and efficient, resulting in a greater demand for digitalization. A key pillar of the digital transformation is communication and in particular the way in which health- and social-care institutions interact. A solid IT infrastructure is key to the development of a future-proof way of working.

Today there is a sizeable gap between the available technologies and the technical solutions used by health- and social-care organizations. Cambio's solutions address that technology gap, resulting in a strong and sustainable demand for our offerings on a global scale.

Liquid funds and cash conversion

By the end of September, Cambio's cash amounted to 134.7 MSEK. Additionally, Cambio has a non-utilized credit facility amounting to 100 MSEK.

Cambio's strong cash conversion is driven by maintenance fees invoiced one year in advance, and a low level of capital expenditures and capitalized R&D that has been stable over recent periods. Since most of the invoices are issued in the fourth quarter of each year, a quarterly comparison of Cambio's cash conversion does not provide for an adequate and fair picture.

Cash conversion by the end of 2019 amounted to 133.0%, which is in line with the past five years' average of 138.9%.

Leverage

By the end of the third quarter the leverage amounted to 2.8 x LTM Q3-20 EBITDA. The leverage is calculated according to the table on the right-hand side. This calculation is in line with the definitions agreed in the existing bond terms.

Balance sheet

Cambio's fixed assets amount to 89.0%, of which 86.2% refer to intangible assets subject to impairment tests. Management believes that these assets provide for a solid foundation to drive future profitability and growth.

The external interest-bearing loans amounted to 547.3 MSEK of which 497.4 MSEK refers to utilized bond facility and 48.7 MSEK refers to financial lease liability with regards to IFRS 16. 1.2 MSEK refers to a bank loan in MittVaccin that was resolved in October.

The Senior Secured 500 MSEK bond rolls with a 3-months-STIBOR + 4.25%. In order to reduce that exposure Sanolium AB has entered into an Interest Rate Cap Transaction with DNB BANK ASA. In conjunction to that Sanolium AB has secured the floating part of the interest on half of the bond value, 250 MSEK, to a maximum of 0.188%. The termination date of this derivative is 26-03-2023.

Products and technology

Cambio's vision is to enable tomorrow's healthcare today. This will be achieved in close cooperation with regions, municipalities and private companies and with continued investments in innovation and technology to further strengthen our product offering.

Cambio COSMIC, is a healthcare information system used in university hospitals, primary care clinics and community care homes. Cambio COSMIC is built on a modern proprietary platform with a wide range of associated subsystems supporting various healthcare disciplines.



Cambio VIVA is used in municipalities. It is an operating system used to coordinate the activities and processes of social services, healthcare and care professionals. VIVA's proprietary platform enables a digital working environment supporting work processes and organizational developments and changes.

In addition to these two major product categories, Cambio also offers other connected services and solutions. Cambio is also preparing and planning to deliver Software-as-a-Service offerings in the future.

Leverage, MSEK

Liability	498.6
Financial lease K3	1.7
Cash	-134.7
80 percent of deferred income	96.1
Net debt (Liability-surplus cash)	461.7
Applicable LTM EBITDA	167.4
Leverage (Net debt/EBITDA)	2.8x

Balance sheet



Cambio COSMIC health care information system. Improving the efficiency of daily tasks and patient outcomes for 100.000 users.

Customers

Today, Cambio has active users in 8 out of 21 regions in Sweden, covering 22.7% of the Swedish population and 26.0% of the end users. Cambio Viva is covering 39 out of the 290 municipalities in Sweden, covering 14.6% of the Swedish population and 12.0% of the end users. Including the newly agreed option regions within the Sussa customer group, Cambio will cover 17 out of 21 regions in Sweden.

Including the Sussa customer group Cambio will cover 17 out of 21 regions in Sweden with Cosmic, which means that Cambio would cover 46.3% of the Swedish population and 51.0% of the end users.

The ambition is to increase the number of customers and to increase the depth and breadth of our product offering so that end users benefit from as much support and help as possible. In Denmark, Cambio offers a wide range of products and our ambition is to reach more end-users with relevant offerings.

Sustainability

Cambio's business model is built on accelerating sustainability in organizations within health- and social-care. Cambio's sustainability report is published on www.cambiogroup.com under Investor Relations.



Market and legislation

The market for delivering e-Health software services is regulated by the Medical Device Directive MDD 93/42/EEC. This regulation will be replaced in 2021 by the Medical Device Regulation MDR 2017/45 .

Almost all tenders ask for a certified Quality Management System, an active Environmental work, and an active Information Security Work. Cambio has the most relevant ISO certifications for the business, such as ISO 9001, 14001, 20000 and 27001.

Most of our customers are publicly financed organizations who are subject to rules and regulations regarding public tender processes. In conjunction with this Cambio needs to be fully aware of those formal processes and act within those frameworks.

Since Cambio handles sensitive information about specific patients we comply with GDPR.

Risks

The group's operations are exposed to a number of financial risks such as market risks (currency risk and interest risk), credit risk and liquidity risk. The group aims to minimize potential adverse effects of these risks on the group's financial results.

The group's exposure to currency risk consists primarily of transactions taking place in foreign currencies between subsidiaries of Cambio. The company does not use derivative instruments in order to reduce currency risks at present.

**17 of 21
regions**

Since Sanolium AB in September 2019 issued a senior secured bond for a total amount of 500 MSEK, the company is exposed to interest rate trends. The bond terms give the investors a yield of STIBOR 3M + 4.25%. In order to reduce that exposure Sanolium AB has entered into an Interest Rate Cap Transaction with DNB BANK ASA. The implication of the transaction is that Sanolium AB has secured the floating part of the interest on half of the bond value, 250 MSEK, to a maximum of 0.188%. The termination date of the derivative is 26-03-2023. The derivative is valued at fair value according to a technique based on fully observable market information.

For a more detailed description of the risks mentioned above and other risks and uncertainties, please refer to the Annual Report 2019.

Transactions with related parties

Sanolium AB is the senior parent company in the group. Related parties consist of all subsidiaries and senior executives in the group and their Related parties. Transactions take place on market terms.

The extent and nature of transactions with related parties in the period is consistent with previous year's transactions with related parties, as described in the 2019 annual report.

This interim report has not been subject to external audit.

Stockholm, 27 November 2020

Peter Gille

CEO

Sebastian Inger

Chairman of the board

Fredrik Rüdén

Board member

Arash Noujoumi

Board member

Consolidated income statement


MSEK	Q3 2020	Q3 2019	Jan-Sep 2020	Feb-Sep 2019
License revenue	12.8	12.6	69.1	34.3
Maintenance revenue	106.9	97.5	314.4	234.5
Professional services	27.0	20.9	98.9	47.9
Other revenue	11.8	6.5	36.4	18.0
Revenue	158.5	137.5	518.8	334.7
Cost of services provided	-11.0	-5.9	-38.2	-15.6
Gross profit	147.5	131.6	480.6	319.1
Employee related expenses	-95.6	-88.8	-310.3	-224.2
Facilities	-0.5	-1.9	-4.3	-5.1
Marketing	-0.3	-1.5	-2.4	-4.7
Travel	-0.3	-1.9	-2.4	-5.6
Other expenses	-7.1	-4.9	-17.3	-12.4
Total operating expenses	-103.8	-99.0	-336.7	-252.0
Adjusted EBITDA	43.7	32.6	143.9	67.1
Depreciation	-38.2	-33.8	-110.0	-83.3
Adjusted EBIT	5.5	-1.2	33.9	-16.2
Non recurring items	-3.3	-44.5	-14.2	-77.2
EBIT	2.2	-45.7	19.7	-93.4
Financial net	-6.7	-4.6	-20.0	-13.9
Income before tax	-4.5	-50.3	-0.3	-107.3
Tax	0.7	4.8	-0.7	12.0
Net Income	-3.8	-45.5	-1.0	-95.3

Consolidated statement of Comprehensive income

MSEK	Q3 2020	Q3 2019	Jan-Sep 2020	Feb-Sep 2019
Net Income/loss	-3.8	-45.5	-1.0	-95.3
Exchange differences in translating foreign operations	-1.0	-0.9	-3.3	0.5
Total comprehensive income for the period	-4.8	-46.4	-4.3	-94.8
<i>Total comprehensive income attributable to:</i>				
Equity holders of the parent company	-4.8	-46.4	-4.3	-94.8
Non controlling interest	NA	NA	NA	NA

Non-Recurring items relating to:

MSEK	Q3 2020	Q3 2019	Jan-Sep 2020	Feb-Sep 2019
Contribution from decided divestment		-17.8	-3.6	-17.8
Advisory fees mergers and acquisitions		-2.8	-1.5	-35.5
New ERP system	-2.2		-7.5	
Refinancing		-23.9		-23.9
Other	-1.1		-1.6	
Total non-recurring items	-3.3	-44.5	-14.2	-77.2



The app Min Hälsa contains all information a patient would need in relation with healthcare.

Consolidated Balance Sheet

MSEK	2020-09-30	2019-12-31
<i>Fixed Assets</i>		
Intangible assets	2,071.3	2,094.7
Tangible assets	15.7	15.6
Right-of-use assets	47.9	26.1
Financial assets	3.3	3.7
Total Fixed Assets	2,138.2	2,140.1
<i>Current Assets</i>		
Inventory	0.2	0.3
Work in progress	43.1	66.0
Accounts receivables	55.9	94.4
Other receivables	2.5	7.3
Tax receivables	4.7	2.6
Prepaid expenses, accrued income	23.7	22.2
Cash	134.7	337.1
Total Current Assets	264.8	529.9
Total Assets	2,403.0	2,670.0
<i>Equity</i>		
Share capital	1.7	1.7
Non-restricted equity	1,149.3	1,258.2
Net income for the period	-1.0	-105.7
Total Equity	1,150.0	1,154.2
Provisions	14.6	12.9
Total Financial Liabilities	498.6	497.3
<i>Other liabilities</i>		
Advance payments	28.0	60.8
Accounts payable	13.2	16.2
Lease liabilities	48.7	26.7
Deferred/ Current Tax liabilities	339.0	350.9
Other liabilities	129.1	127.3
Accrued expenses	61.7	51.7
Deferred income	120.1	372.0
Total Other Liabilities	739.8	1,005.6
Total Equity and Liabilities	2,403.0	2,670.0

Changes in group equity

MSEK	Jan-Sep 2020	Feb-Sep 2019
Opening Balance	1,154.2	
Total comprehensive income for the period	-4.2	-94.8
Total change excluding owner transactions	1,150.0	-94.8
New share issue		0.1
Non-cash issue		161.3
Shareholder contributions		1,072.7
Equity at the end of the period	1,150.0	1,139.3
Attributable to equity holders of the parent company	1,150.0	1,139.3
Non-controlling interest	N/A	N/A

Consolidated cashflow statement

MSEK	Jan-Sep 2020	Feb-Sep 2019
Income after financial items	-0.3	-107.3
Adjusted for non-cash items	106.3	83.3
Taxes paid	-9.0	-12.5
Changes in working capital	-225.1	-27.8
Cash flow from operating activities	-128.1	-64.3
Investments in intangibles/tangibles	-32.8	-23.9
Acquisition of shares in subsidiaries and associations	-26.2	-1,372.3
Cashflow from investing activities	-59.0	-1,396.2
New share issue		0.1
Shareholder contributions		1,099.7
Bond issue		500.0
Lease payments	-15.3	-10.7
Cashflow from financing activities	-15.3	1,589.1
Changes in cash and cash equivalents	-202.4	128.6
Opening cash and cash equivalents balance	337.1	
Cash and cash equivalents by end of the period	134.7	128.6

Consolidated Income Statement – Pro Forma

MSEK	Jan-Sep 2020	Jan-Sep 2019
License revenue	69.1	38.6
Maintenance revenue	314.4	287.2
Professional services	98.9	54.3
Other revenue	36.4	21.9
Revenue	518.8	402.0
Cost of services provided	-38.2	-19.0
Gross profit	480.6	383.0
Employee related expenses	-310.3	-271.6
Facilities	-4.3	-6.4
Marketing	-2.4	-5.2
Travel	-2.4	-7.3
Other expenses	-17.3	-14.9
Total operating expenses	-336.7	-305.4
Adjusted EBITDA	143.9	77.6
Depreciation	-110.0	-108.4
Adjusted EBIT	33.9	-30.8
Non recurring items	-14.2	-71.0
EBIT	19.7	-101.8
Financial net	-20.0	-16.0
Income before tax	-0.3	-117.8
Tax	-0.7	15.1
Net Income	-1.0	-102.7

Pro forma figures include the operational figures prior to February 20 when the Sanolium group was founded.

Since the structure in the interim report differs from the annual report, in the table below the year to date consolidated income statement is shown in the annual report format.

Consolidated Income Statement – Annual report format

MSEK	Jan-Sep 2020	Feb-Sep 2019
Net sales	482.4	315.3
Other revenue	36.4	18.4
Capitalized R&D	26.5	18.5
Total	545.3	352.2
Other external expenses	-125.3	-112.6
Personnel cost	-290.3	-188.2
Depreciation	-110.0	-83.3
Operating income	19.7	-31.9
Financial net	-20.0	-75.4
Income before tax	-0.3	-107.3
Tax	-0.7	12.0
Net Income	-1.0	-95.3

Segment reporting

The group recognizes only a single segment in accordance with the definition of operating segment in IFRS 8. The starting point for identifying operating segments on which separate information can be provided are the internal reports to and monitoring by the group management. The group management monitors operating income for the entire business as one operating segment.

Timing of revenue

MSEK	Q3 2020	Q3 2019	Jan-Sep 2020	Feb-Sep 2019
Timing of revenue recognition				
At a point in time	51.6	40.0	204.4	100.2
Over time	106.9	97.5	314.4	234.5
	158.5	137.5	518.8	334.7

"At a point in time" is defined as revenue correlated to working hours while "over time" is not.

Intangible assets

MSEK	Capitalised development expenditure	Customer contracts/ accrued revenues	Trademarks	Technology	Goodwill	Total
At 31 Dec 2019	78.9	573.6	87.7	918.1	436.4	2,094.7
Acquisitions for the period	30.2	6.3	0.4	0.3	31.2	68.4
Disposals						
Depreciation for the period	-8.6	-32.3		-48.6		-89.5
Exchange rate changes	0.5			2.1	-4.9	-2.3
At 30 Sep 2020	101.0	547.6	88.1	871.9	462.7	2,071.3

APPLICABLE ACCOUNTING RULES

Sanolium AB complies with IFRS standards and interpretations (IFRIC) as adopted by the EU. This Interim Report has been prepared in accordance with IAS 34 Interim Financial Reporting. The Parent Company's financial statements have been prepared in accordance with RFR 2. The accounting policies applied are consistent with those presented in the Annual Report for 2019, except for the adoption of standard amendments effective as of January 1, 2020. The amendments are not expected to have any material impact on the financial statements.

Detailed information about the Group's accounting and valuation principles can be found in the Annual Report for 2019 which is available on www.cambio.se.

This interim report refers to certain key performance indicators which Cambio and others use when evaluating the performance of Cambio. These are referred to as alternative performance measures (APMs) and are not defined under IFRS. The figures give management and investors important information and enable both to analyze Cambio's business and trends. The APMs are not meant to replace but to complement the performance measures defined under IFRS.

Parent company

Sanolium AB is a holding company that invests in fast-growing companies within the e-health industry. The company is one of the largest e-Health companies in Northern Europe and has the ambition to grow faster than the market through organic opportunities as well as acquisitions. This should be done in a profitable and sustainable manner. Sanolium AB's operational subsidiaries' vision is to enable tomorrow's healthcare today.

The operating entities mainly deliver products and services in Sweden under the names Cambio COSMIC and Cambio VIVA.

Sanolium AB has no employees.

Income Statement Parent Company

MSEK	Q3 2020	Q3 2019	Jan-Sep 2020	Feb-Sep 2019
Other revenue			2.9	3.1
Revenue			2.9	3.1
Employee related expenses	-0.1		-2.9	-3.1
Other expenses				-0.1
Total operating expenses	-0.1		-2.9	-3.2
Adjusted EBITDA	-0.1		0.0	-0.1
Non recurring items		-23.3	-0.8	-23.9
EBIT	-0.1	-23.3	-0.8	-24.0
Financial net	-6.4	-4.7	-19.8	-11.3
Net Income	-6.5	-28.0	-20.6	-35.3



Balance sheet Parent Company

MSEK	2020-09-30	2019-12-31
<i>Fixed Assets</i>		
Financial assets	1,815.0	1,815.7
Total Fixed Assets	1,815.0	1,815.7
<i>Current Assets</i>		
Other receivables		1.6
Other receivables - Group	7.3	4.0
Prepaid expenses and accrued income	0.2	0.1
Cash	6.0	10.8
Total Current Assets	13.5	16.5
Total Assets	1,828.5	1,832.2
<i>Equity</i>		
Share capital	1.7	1.7
Non-restricted equity	1,215.3	1,259.0
Net income for the year	-20.6	-43.7
Total Equity	1,196.4	1,217.0
Total Financial Liabilities	497.4	496.9
<i>Other liabilities</i>		
Other liabilities	99.4	99.4
Other liabilities - Group	35.0	18.6
Accrued expenses	0.3	0.3
Total Other Liabilities	134.7	118.3
Total Equity and Liabilities	1,828.5	1,832.2

Changes in Parent company equity

MSEK	Jan-Sep 2020	Feb-Sep 2019
Opening Balance	1,217.0	
Total comprehensive income for the period	-20.6	-35.3
Total change excluding owner transactions	1,196.4	-35.3
New share issue		0.2
Non-cash issue		160.9
Shareholder contributions		1,099.7
Equity at the end of the period	1,196.4	1,225.4
Attributable to equity holders of the parent company	1,196.4	1,225.4
Non-controlling interest	N/A	N/A

Parent company cash flow

MSEK	Jan-Sep 2020	Feb-Sep 2019
Income after financial items	-20.6	-35.3
Changes in working capital	15.8	149.3
Cash flow from operating activities	-4.8	114.0
Acquisition of shares in subsidiaries and associations		-1,654.8
Cashflow from investing activities		-1,654.8
New share issue		0.1
Shareholder contributions		1,099.7
Bond issue		500.0
Cashflow from financing activities		1,599.8
Changes in cash and cash equivalents	-4.8	58.9
Opening cash and cash equivalents balance	10.8	
Cash and cash equivalents by end of the period	6.0	58.9

Definitions

Adjusted EBIT

Income before non recurring items, financial net and tax.

Adjusted EBITDA

Income before depreciation, non recurring items, financial net and tax.

Adjusted EBITDA margin

Adjusted EBITDA as a percentage of revenue.

Cash conversion

Operating cash flow divided by adjusted EBITDA.

EBIT

Income before financial net and tax.

Non recurring items

Items excluded from the normal operating items e.g restructuring costs, costs related to introduction of a new ERP system, M&A related costs and costs regarding refinancing or to set a financing structure (excluding interest on external debt).

Operating cash flow

Adjusted EBITDA minus capital expenditures, capitalized R&D and net working capital changes.

Financial calendar

Annual General Meeting, 2021-05-04
Interim report Q4. Full year, 2021-02-19
Interim report Q1, January-March 2021-05-31
Interim report Q2 January-June, 2021-08-19
Interim report Q3 January-September, 2021-11-30



Presentation of the interim report

Cambio's interim reports will be published at cambio.com at each of the dates stipulated above.

Information

For further information, please contact:
Fredrik Rüdén, CFO +46 760 018 422
fredrik.ruden@cambio.se



Sanolium AB

Cambio Healthcare Systems AB
Drottninggatan 89
113 60 Stockholm

+46 8 691 49 00
info@cambio.se

